Literature DB >> 11689576

Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same.

R J Mayer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11689576     DOI： 10.1200/JCO.2001.19.21.4093

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Management of a locally advanced rectal cancer in a patient who declined surgery.

Authors:  Raafat Alameddine; David Wehbe; Martin Weiser; Neil Segal; Karyn Goodman; Ali Shamseddine; Celina Ang; Ali Haydar; Mustafa Sidani; Fady Geara; Mohamed Naghy; Eileen M O'Reilly; Ghassan K Abou-Alfa
Journal:  Gastrointest Cancer Res       Date:  2012-11

2.  Risk and management of venous thromboembolisms in bevacizumab-treated metastatic colorectal cancer patients.

Authors:  Irene Yu; Leo Chen; Jenny Y Ruan; Jennifer T Chang; Winson Y Cheung
Journal:  Support Care Cancer       Date:  2015-08-19       Impact factor: 3.603

3.  Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.

Authors:  J Feliu; J M Vicent; C García-Girón; M Constela; E Fonseca; J Aparicio; M Lomas; L Antón-Aparicio; F J Dorta; M Gonzalez-Baron
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640

4.  XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancer.

Authors:  Chengxu Cui; Chang Shu; Yi Yang; Junbao Liu; Shuping Shi; Zhujun Shao; Nan Wang; Ting Yang; Songnian Hu
Journal:  Oncol Lett       Date:  2014-07-10       Impact factor: 2.967
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.